Pharming Group (OTCMKTS:PHGUF) Shares Gap Up – Should You Buy?

Pharming Group NV (OTCMKTS:PHGUF) shares gapped up prior to trading on Wednesday . The stock had previously closed at $1.20, but opened at $1.25. Pharming Group shares last traded at $1.25, with a volume of 200 shares traded.

Pharming Group Price Performance

The stock has a market cap of $771.73 million, a PE ratio of 57.53 and a beta of 0.45. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.63 and a quick ratio of 2.06. The firm’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.61.

Pharming Group (OTCMKTS:PHGUF) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The business had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.